Your browser doesn't support javascript.
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.
Titanji, Boghuma K; Farley, Monica M; Mehta, Ashish; Connor-Schuler, Randi; Moanna, Abeer; Cribbs, Sushma K; O'Shea, Jesse; DeSilva, Kathryn; Chan, Bonnie; Edwards, Alex; Gavegnano, Christina; Schinazi, Raymond F; Marconi, Vincent C.
  • Titanji BK; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Farley MM; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Mehta A; Infectious Diseases, Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA.
  • Connor-Schuler R; Pulmonary Medicine, Atlanta Veterans Affairs Medical Center, Department of Medicine, Decatur, Georgia, USA.
  • Moanna A; Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University, Atlanta, Georgia, USA.
  • Cribbs SK; Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University, Atlanta, Georgia, USA.
  • O'Shea J; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.
  • DeSilva K; Infectious Diseases, Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA.
  • Chan B; Pulmonary Medicine, Atlanta Veterans Affairs Medical Center, Department of Medicine, Decatur, Georgia, USA.
  • Edwards A; Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University, Atlanta, Georgia, USA.
  • Gavegnano C; Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Schinazi RF; Infectious Diseases, Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA.
  • Marconi VC; Infectious Diseases, Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA.
Clin Infect Dis ; 72(7): 1247-1250, 2021 04 08.
Article in English | MEDLINE | ID: covidwho-1174886
ABSTRACT
Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid